Unjha Formulations Limited carries a market capitalization of 87.37M, placing it among publicly traded companies globally. Its enterprise value stands at 73.83M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 87.37M |
| Enterprise Value | 73.83M |
Unjha Formulations Limited currently has 4.48M shares outstanding.
| Shares Outstanding | 4.48M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Unjha Formulations Limited trades at a trailing price-to-earnings ratio of 12.81. The price-to-sales ratio is 0.58, and the price-to-book ratio stands at 2.02.
| PE Ratio | 12.81 |
| PS Ratio | 0.58 |
| PB Ratio | 2.02 |
| P/TBV Ratio | 2.70 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
On an enterprise value basis, Unjha Formulations Limited trades at an EV/EBITDA multiple of 8.21 and an EV/FCF ratio of 1,281.25. The EV/Sales ratio of 0.47 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 8.21 provides insight into valuation relative to core operating earnings.
| EV / Sales | 0.47 |
| EV / EBITDA | 8.21 |
| EV / EBIT | 8.21 |
| EV / FCF | 1,281.25 |
Unjha Formulations Limited maintains a current ratio of 2.53, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.53 |
| Quick Ratio | 0.99 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | 115.29 |
Unjha Formulations Limited posts a return on equity of 18.50 and a return on invested capital of 19.02.
| Return on Equity (ROE) | 18.50 |
| Return on Assets (ROA) | 14.00 |
| Return on Invested Capital (ROIC) | 19.02 |
| Return on Capital Employed (ROCE) | 18.65 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 14.47 |
Over the trailing twelve months, Unjha Formulations Limited has paid 2.49M in income taxes, reflecting an effective tax rate of 26.12.
| Income Tax | 2.49M |
| Effective Tax Rate | 26.12 |
Unjha Formulations Limited's stock has declined approximately -15.18051% over the past 52 weeks. The 50-day moving average sits at 19.84, while the 200-day moving average is 22.34.
| Beta (5Y) | N/A |
| 52-Week Price Change | -15.18051% |
| 50-Day Moving Average | 19.84 |
| 200-Day Moving Average | 22.34 |
| Average Volume (20 Days) | N/A |
Over the trailing twelve months, Unjha Formulations Limited generated 155.85M in revenue and converted that into 7.05M in net income, yielding earnings per share of 1.58. EBITDA reached 8.99M, while operating income came in at 8.99M.
| Revenue | 155.85M |
| Gross Profit | 35.46M |
| Operating Income | 8.99M |
| Pretax Income | 9.54M |
| Net Income | 7.05M |
| EBITDA | 8.99M |
| EBIT | 8.99M |
| Earnings Per Share (EPS) | 1.58 |
Total book value stands at 44.81M, with working capital of 25.45M providing operational flexibility.
| Cash & Cash Equivalents | 16.45M |
| Total Debt | N/A |
| Net Debt | -16.45M |
| Equity (Book Value) | 44.81M |
| Book Value Per Share | 10.07 |
| Working Capital | 25.45M |
Unjha Formulations Limited operates with a gross margin of 22.75, reflecting its pricing power and cost economics. The operating margin of 5.77 and net profit margin of 4.52 provide insight into operational efficiency.
| Gross Margin | 22.75 |
| Operating Margin | 5.77 |
| Pretax Margin | 6.12 |
| Profit Margin | 4.52 |
| EBITDA Margin | 5.77 |
Unjha Formulations Limited posts an Altman Z-Score of 7.56, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 7.56 |